TELA Bio (TELA) Stock Price, News & Analysis

Company Overview

TELA Bio, Inc. is a medical technology company that develops and commercializes advanced tissue-reinforcement products for soft-tissue repair and reconstruction. The company’s products are designed to support the repair of damaged or weakened tissue while preserving a more natural tissue response.

TELA Bio’s principal product platform is OviTex Reinforced Tissue Matrix, which combines biologic tissue with polymer reinforcement in a proprietary, textile-like design. OviTex products are used in procedures involving hernia and abdominal wall repair, as well as other soft-tissue reconstruction applications. The company also offers products intended for plastic and reconstructive surgery and related surgical specialties.

Founded in 2012 and headquartered in Malvern, Pennsylvania, TELA Bio primarily serves the U.S. surgical market through its commercial organization and distribution relationships. The company’s products are used by surgeons and hospitals seeking alternatives for soft-tissue reinforcement and reconstruction.

Key Stats

• Today's Range: $0.66 to $0.95
• 50-Day Range: $0.75 to $1.41
• 52-Week Range: $0.50 to $1.50
• Volume: 773,441 shs
• Average Volume: 120,471 shs
• Market Capitalization: $42.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.14
• Consensus Rating: Moderate Buy

TELA Bio Stock Analysis - MarketRank™

TELA Bio scored higher than 78% of companies evaluated by MarketBeat, and ranked 114th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TELA Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

TELA Bio has a consensus price target of $2.14, representing about 127.5% upside from its current price of $0.94.

Amount of Analyst Coverage

TELA Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TELA Bio are expected to grow in the coming year, from ($0.76) to ($0.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TELA Bio is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TELA Bio is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TELA Bio has a P/B Ratio of 5.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.30% of the float of TELA Bio has been sold short.

Short Interest Ratio / Days to Cover

TELA Bio has a short interest ratio ("days to cover") of 5.07.

Change versus previous month

Short interest in TELA Bio has recently decreased by 9.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TELA Bio does not currently pay a dividend.

Dividend Growth

TELA Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.49

News Sentiment

TELA Bio has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for TELA Bio this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added TELA Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of TELA Bio in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $119,500.00 in company stock, which represents 0.2811% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, TELA Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.10% of the stock of TELA Bio is held by insiders.

Percentage Held by Institutions

94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:TELA
• CIK: 1561921
• Web: www.telabio.com
• Phone: 484-320-2930
• Fax: N/A
• Employees: 218
• Year Founded: 2012

Price Target and Rating

• Average Price Target for TELA Bio: $2.14
• High Price Target: $3.00
• Low Price Target: $1.00
• Potential Upside/Downside: +127.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.83 million
• Net Margins: -53.57%
• Pretax Margin: -51.20%
• Return on Equity: -1,320.81%
• Return on Assets: -55.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.99
• Quick Ratio: 2.38

Sales & Book Value

• Annual Sales: $78.18 million
• Price / Sales: 0.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.16 per share
• Price / Book: 5.89

Miscellaneous

• Outstanding Shares: 45,143,000
• Free Float: 44,646,000
• Market Cap: $42.52 million
• Optionable: Optionable
• Beta: 1.46